Clean ClAImsFirst Pass

Accuity

Physician-led pre-bill chart review that recovers earned revenue

Our take

Accuity provides a second-level clinical documentation and coding review that runs post-discharge and pre-bill, after a hospital's own CDI and coding work is complete. Its Amplifi AI engine, trained on more than 7 million chart outcomes, flags charts with likely documentation or coding gaps; 185 multi-specialty physicians plus coders and CDI specialists then review and correct them before the bill drops. Buyers are CFOs, revenue cycle leaders, and CDI/HIM leaders at hospitals who want revenue their teams miss captured compliantly, with a reported 1.5% final denial rate on reviewed cases.

Founded in 2016 by hospital-based physicians and headquartered in Mount Laurel, NJ, Accuity works with more than 50 clients across 400+ hospital sites, including 4 of the top 10 US health systems and Temple Health. It reports $4-6M of net cash recovered per 10,000 inpatient discharges, over $600M in annualized client benefit, and $3.3B in cumulative revenue lift. The engagement model is performance based, opening with a 60-day pilot at no upfront fee. It earned HITRUST r2 certification in 2025. The trade-off versus software: stronger results guarantees, but an ongoing service dependency.

What it does

  • Post-discharge, pre-bill second-level chart review
  • Amplifi AI trained on 7M+ chart outcomes
  • 185 multi-specialty physicians review flagged cases
  • DRG, CC/MCC, and quality metric capture
  • Medicaid expertise across 38 states
  • Compliance oversight with 1.5% final denial rate

Where it's strong

  • Runs after your CDI and coding teams finish, so it adds a safety net without changing their workflow.
  • Scale is proven: 400+ hospital sites, 4 of the top 10 US health systems, and $3.3B in client revenue lift.
  • Performance-based pricing with a 60-day pilot and no upfront fees keeps buyer risk low.

What buyers should weigh

  • It is a service engagement, not software your team operates, so capability does not transfer in-house.
  • Fees come out of recovered revenue, which costs more at scale than licensing a tool.
  • Focused on inpatient pre-bill review; it does not address front-end or denial workflows.

Latest

Reported more than $600M in annualized net cash benefit across 50+ clients and earned HITRUST r2 certification in 2025.

Also in Revenue Integrity & Pre-Bill Review

Track this market

First Pass covers Revenue Integrity & Pre-Bill Review and the rest of the getting-paid stack every week.